Celularity Inc. Announces Receipt of Nasdaq Notification

Core Viewpoint - Celularity Inc. has received a notification from Nasdaq regarding non-compliance with continued listing requirements due to the delay in filing its Quarterly Report on Form 10-Q for Q3 2024, but the company's stock continues to trade on Nasdaq [1][2]. Compliance and Reporting - The company is required to submit a plan to Nasdaq to regain compliance by January 20, 2025, and if accepted, has until May 13, 2025, to implement the plan [2]. - The delay in filing the Q3 Form 10-Q is attributed to a backlog from previous filings, including the Forms 10-Q for the first and second quarters of 2024, which have been filed recently [3]. Management Commitment - The CEO of Celularity has acknowledged the challenges posed by the filing delays but emphasized the company's commitment to robust and timely financial reporting, stating that the Q3 Form 10-Q is nearing completion [4]. Company Overview - Celularity Inc. focuses on developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, targeting aging-related diseases, cancer, and immune disorders [5].